Pharmacoeconomic analysis of perioperative chemo-immunotherapy in resectable stage III non small cell lung cancer (NSCLC): Survival time cost-efficacy based on NADIM 2 trial.

Authors: Bartomeu Massuti, Ernest Nadal, Jose-Luis Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabé, Joaquim Bosch-Barrera, Martín Lázaro, Virginia Calvo, Amelia Insa, Santiago Ponce Aix, Noemi Reguart, Javier De Castro, Rosario Garcia Campelo, Carlos Camps, Manuel Cobo, Santiago Viteri, Eider Azkona, Eva Pereira, Mariano Provencio,

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e23141

Source: Full article

---

Abstract

e23141